References
- 1. Ryerson C, Vittinghoff E, Ley B, Lee J, Mooney J, Jones K, et al. Predicting survival across chronic interstitial lung disease. Chest. 2014;145: 723–728.10.1378/chest.13-147424114524
- 2. Park JH, Kim DS, Park I-N, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia. American Journal of Respiratory and Critical Care Medicine. 2007;175: 705–711.10.1164/rccm.200607-912OC17218621
- 3. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine. 2012;156: 684–691.10.7326/0003-4819-156-10-201205150-0000422586007
- 4. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. European Respiratory Journal. 2012;40: 101–109.10.1183/09031936.0010601122241745
- 5. Bois RMD, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2011;184: 459–466.10.1164/rccm.201011-1790OC21616999
- 6. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2000;161: 487–492.10.1164/ajrccm.161.2.990601510673190
- 7. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respiratory Medicine. 2009;103: 117–123.10.1016/j.rmed.2008.07.02218786822
- 8. Celli BR, Cote CG, Marin JM, Casanova C, MM de Oca, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. The New England Journal of Medicine. 2004;350: 1005–1012.10.1056/NEJMoa02132214999112
- 9. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official american thoracic society/european respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine. 2013;188: 733–748.10.1164/rccm.201308-1483ST580365524032382
- 10. Bendstrup E, Maher T, Manali E, Wijsenbeek M. Challenges in the classification of fibrotic ILD. Sarcoidosis Vasculitis and Diffuse Lung Disease 2015;32(Suppl 1): 4–9.
- 11. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr., et al; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Annals of Internal Medicine. 2005;142: 963–967.10.7326/0003-4819-142-12_Part_1-200506210-00005
- 12. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2021. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf.
- 13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Updated 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.
- 14. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al; International Association for the Study of Lung Cancer International Staging Committee. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Journal of Thoracic Oncology. 2007;2: 706–714.10.1097/JTO.0b013e31812f3c1a17762336
- 15. Low S. Using the ILD-GAP model to predict mortality in chronic interstitial lung disease. European Respiratory Journal. 2015;46(Suppl 59): PA3824. doi: 10.1183/13993003.congress-2015.PA3824.10.1183/13993003.congress-2015.PA3824
- 16. Ley B, Collard HR, TE King Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011;183: 431–440.10.1164/rccm.201006-0894CI20935110
- 17. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique-1995 update. American Journal of Respiratory and Critical Care Medicine. 1995;152: 2185–2198.10.1164/ajrccm.152.6.85207968520796
- 18. Jensen RL, Carpo RO. Diffusion capacity: how to get it right. Respiratory Care. 2003;48: 777–782.
- 19. Lederer DJ, Arcasoy SM, Wilt JS, D’ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2006;174: 659–664.10.1164/rccm.200604-520OC264805716778159
- 20. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respiratory Medicine. 2010;104: 1035–1041.10.1016/j.rmed.2010.02.00820199856
- 21. Behr J, Ryu J. Pulmonary hypertension in interstitial lung disease. European Respiratory Journal. 2008;31: 1357–1367.10.1183/09031936.0017130718515559
- 22. Corte TJ, Wort SJ, Talbot S, Macdonald PM, Hansell DM, Polkey M. et al. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2012;29: 41–50.
- 23. du Bois R, Albera C, Bradford W, Costabel U, Leff J, Noble P, et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 2013;43: 1421–1429.10.1183/09031936.0013181324311766